Kumamoto Shinto General Hospital
Kumamoto, Japan
Private hospital in Kumamoto
3 Chome-2-65 Oe, Chuo Ward, Kumamoto, 862-8655
About Kumamoto Shinto General Hospital
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Eli Lilly and Company
6
Hoffmann-La Roche
4
Gilead Sciences
3
Pfizer
2
Amgen
1
Incyte Corporation
1
Janssen Research & Development, LLC
1
Clinical Trials at Kumamoto Shinto General Hospital
During the past decade, Kumamoto Shinto General Hospital conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 8 clinical trials were completed, i.e. on
average, 53.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 7 clinical trials were completed. i.e. 116.7%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
2012-10-19
2018-10-25
Completed
61
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
2013-06-27
2020-11-12
Completed
2,877
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
2013-07-09
2015-12-15
Completed
254
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
2017-02-13
2019-06-19
Terminated
808
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
2017-01-30
2019-05-06
Terminated
883
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
2017-07-12
2029-06-24
Active, not recruiting
5,637
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
2018-01-06
2023-01-04
Completed
580
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
2018-08-02
2025-08-24
Active, not recruiting
2,300
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Kumamoto Shinto General Hospital" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Hoffmann-La Roche" with 4 trials
sponsored, "Gilead Sciences" with 3 trials sponsored, "Pfizer" with 2 trials sponsored and "Amgen"
with 2 trials sponsored. Other sponsors include -3 different institutions and
companies that sponsored additional 7 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Kumamoto Shinto General Hospital"
#1 collaborator was "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator and "Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 6 trials.
Clinical Trials Conditions at Kumamoto Shinto General Hospital
According to Clinical.Site data, the most researched conditions in "Kumamoto Shinto General Hospital" are
"Breast Cancer" (4 trials), "Breast Neoplasms" (4 trials), "Nonalcoholic Steatohepatitis" (3 trials), "Anemia" (1 trials) and "Hepatitis C Virus Infection" (1 trials). Many other conditions were trialed in "Kumamoto Shinto General Hospital" in a lesser frequency.
Clinical Trials Intervention Types at Kumamoto Shinto General Hospital
Most popular intervention types in "Kumamoto Shinto General Hospital" are "Drug" (18 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (7 trials), "Paclitaxel" (4 trials), "Abemaciclib" (3 trials), "Atezolizumab" (3 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Kumamoto Shinto General Hospital
The vast majority of trials in "Kumamoto Shinto General Hospital" are
17 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Kumamoto Shinto General Hospital
Currently, there are NaN active trials in "Kumamoto Shinto General Hospital".
undefined are not yet recruiting,
3 are recruiting,
7 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in Kumamoto Shinto General Hospital,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Kumamoto Shinto General Hospital, 1 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 12 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".